Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812925 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
A Phase 3 study of Primary Immune Thrombocytopenia, sponsored by argenx.
- Active
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 20
- Study locations
NCT04812925 is a Phase 3 study of Primary Immune Thrombocytopenia that is active but no longer recruiting, run by argenx. The registered enrollment target is 173 participants, above the 96-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT04812925, a Phase 3 study of Primary Immune Thrombocytopenia, is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia
Conditions Studied
Interventions
- BIOLOGICAL efgartigimod PH20 SC
Study Locations (20)
Other
- Investigator Site 0540001 - Buenos Aires
- Investigator site 540004 - Buenos Aires
- Investigator Site 0610012 - Garran
- Investigator Site 0610003 - West Perth
- Investigator site 610005 - Westmead
- Investigator Site 3590017 - Plovdiv
- Investigator site 0560003 - Reñaca
- Investigator site 560002 - Santiago
- Investigator site 0560004 - Temuco
- Investigator site 860013 - Beijing
- Investigator Site 0860008 - Bengbu
- Investigator site 860055 - Huizhou
- Investigator Site 0860015 - Shenzhen
- Investigator Site 0860001 - Tianjin
- Investigator Site 0860010 - Wuhan
Arkansas
- Investigator Site 0010116 - Bentonville
District of Columbia
- Investigator site 0010045 - Washington D.C.
Indiana
- Investigator Site 0010062 - Fort Wayne
Iowa
- Investigator site US0010042 - Iowa City
Oklahoma
- Investigator Site 0010095 - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04812925
The ClinicalTrials.gov registry entry for NCT04812925 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (80% higher). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which efgartigimod PH20 SC is the first listed.
NCT04812925 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Arkansas, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04812925 about?
NCT04812925 is a clinical study titled "A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia". A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia
What is the current status of trial NCT04812925?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2021-11-17. Estimated completion is 2026-10-01.
What conditions does trial NCT04812925 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia.
What interventions are being tested in trial NCT04812925?
The interventions under investigation include: efgartigimod PH20 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04812925?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04812925 being conducted?
This trial has 20 study locations across Arkansas, District of Columbia, Indiana, Iowa, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
COMPLETED · Phase 3
-
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
RECRUITING · Phase 2
-
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.